|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We report here a case of osimertinib used at 160 mg once daily in a heavily pretreated patient with EGFR exon 20 T790M-negative advanced NSCLC with LM to achieve a partial response, including shrinkage of the LM, for up to 12 months until further progression.
|
31642175 |
2019 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We report for the first time to our knowledge that V600E and non-V600E BRAF mutations affect different patients with NSCLC.
|
21825258 |
2011 |
|
rs1427028322
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We present a case report of a patient with NSCLC and the BRAF G469R mutation who showed a dramatic response to sorafenib.
|
26237499 |
2015 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We performed preclinical assessments of brain penetration and activity of osimertinib (AZD9291), an oral, potent, irreversible EGFR-TKI selective for EGFRm and T790M resistance mutations, and other EGFR-TKIs in various animal models of EGFR-mutant NSCLC brain metastases.
|
27435396 |
2016 |
|
rs2227983
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We investigated the EGFR mutations and/or R497K polymorphism statuses in 225 surgically treated NSCLC cases.192 adenocarcinoma cases were included.
|
18726117 |
2009 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We hypothesized that treatment with cabozantinib plus erlotinib in <i>EGFR</i> mutation-positive NSCLC following progression on EGFR TKI therapy may allow tumors to overcome this resistance or restore sensitivity to therapy regardless of T790M status.
|
30915273 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We hypothesized that plasma-based EGFR mutation analysis for NSCLC may be feasible for monitoring treatment response to EGFR TKIs and also predict drug resistance.Clinically relevant mutations including exon 19 deletion (ex19del), L858R and T790M were analyzed using droplet digital PCR (ddPCR) in longitudinally collected plasma samples (n = 367) from 81 NSCLC patients treated with EGFR TKI.
|
26755650 |
2016 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We hypothesized that plasma-based EGFR mutation analysis for NSCLC may be feasible for monitoring treatment response to EGFR TKIs and also predict drug resistance.Clinically relevant mutations including exon 19 deletion (ex19del), L858R and T790M were analyzed using droplet digital PCR (ddPCR) in longitudinally collected plasma samples (n = 367) from 81 NSCLC patients treated with EGFR TKI.
|
26755650 |
2016 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We hypothesized that plasma-based EGFR mutation analysis for NSCLC may be feasible for monitoring treatment response to EGFR TKIs and also predict drug resistance.Clinically relevant mutations including exon 19 deletion (ex19del), L858R and T790M were analyzed using droplet digital PCR (ddPCR) in longitudinally collected plasma samples (n = 367) from 81 NSCLC patients treated with EGFR TKI.
|
26755650 |
2016 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We hypothesized that plasma-based EGFR mutation analysis for NSCLC may be feasible for monitoring treatment response to EGFR TKIs and also predict drug resistance.Clinically relevant mutations including exon 19 deletion (ex19del), L858R and T790M were analyzed using droplet digital PCR (ddPCR) in longitudinally collected plasma samples (n = 367) from 81 NSCLC patients treated with EGFR TKI.
|
26755650 |
2016 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We herein report a 73-year-old patient with chronic cough, who was diagnosed with advanced NSCLC with the EGFR mutation of L858R substitution in exon 21, and treated with the combination of oral icotinib and BAI chemotherapy as the first-line therapy, which resulted in a satisfactory clinical outcome.
|
30079342 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We herein report a 73-year-old patient with chronic cough, who was diagnosed with advanced NSCLC with the EGFR mutation of L858R substitution in exon 21, and treated with the combination of oral icotinib and BAI chemotherapy as the first-line therapy, which resulted in a satisfactory clinical outcome.
|
30079342 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We herein report a 73-year-old patient with chronic cough, who was diagnosed with advanced NSCLC with the EGFR mutation of L858R substitution in exon 21, and treated with the combination of oral icotinib and BAI chemotherapy as the first-line therapy, which resulted in a satisfactory clinical outcome.
|
30079342 |
2018 |
|
rs121913444
|
|
|
0.750 |
GeneticVariation |
BEFREE |
We here present an NSCLC patient found to be positive for double uncommon EGFR mutations (G719X and L861Q) by clinical genomic sequencing analysis of a pleural effusion specimen who showed a durable response to the EGFR-TKI afatinib.
|
30255614 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We examined whether T790M is related to clinicopathologic or prognostic factors in patients with relapse of EGFR mutant non-small cell lung cancer (NSCLC) after treatment with 1st or 2nd EGFR-TKIs.
|
27811988 |
2016 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We examined the diagnostic accuracy of the cumulative smoking dose for identifying the epidermal growth factor receptor (EGFR) exon 19 deletion and L858R mutation among Japanese patients with non-small-cell lung cancer (NSCLC).
|
19650855 |
2009 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We examined the diagnostic accuracy of the cumulative smoking dose for identifying the epidermal growth factor receptor (EGFR) exon 19 deletion and L858R mutation among Japanese patients with non-small-cell lung cancer (NSCLC).
|
19650855 |
2009 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We examined the diagnostic accuracy of the cumulative smoking dose for identifying the epidermal growth factor receptor (EGFR) exon 19 deletion and L858R mutation among Japanese patients with non-small-cell lung cancer (NSCLC).
|
19650855 |
2009 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We enrolled patients aged 18-75 years with completely resected (R0), stage II-IIIA (N1-N2), EGFR-mutant (exon 19 deletion or exon 21 Leu858Arg) NSCLC.
|
29174310 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We enrolled patients aged 18-75 years with completely resected (R0), stage II-IIIA (N1-N2), EGFR-mutant (exon 19 deletion or exon 21 Leu858Arg) NSCLC.
|
29174310 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We enrolled patients aged 18-75 years with completely resected (R0), stage II-IIIA (N1-N2), EGFR-mutant (exon 19 deletion or exon 21 Leu858Arg) NSCLC.
|
29174310 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We developed and evaluated liquid biopsy assays for detection of TKI-sensitizing and T790M mutations of EGFR by droplet digital PCR (ddPCR) in EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with acquired EGFR-TKI resistance.
|
27542267 |
2016 |
|
rs2227983
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We determined the genotypes for R497K and intron1 (CA) n repeat genetic polymorphisms of 70 Chinese patients with advanced non-small cell lung cancer.
|
17597605 |
2007 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We conducted a study on "post-progression" (pp) outcomes of T790M EGFR-positive NSCLC patients treated with osimertinib, according to the therapeutic strategy applied: osimertinib beyond progression (± LATs), "switched therapies" or best supportive care only (BSC).
|
31392645 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We assessed the T790M mutation in pretreatment diagnostic specimens from 129 erlotinib-treated advanced NSCLC patients with EGFR mutations.
|
21233402 |
2011 |